Metacrine (NASDAQ:MTCR) Rating Lowered to Hold at Zacks Inve

Metacrine (NASDAQ:MTCR) Rating Lowered to Hold at Zacks Investment Research

Metacrine (NASDAQ:MTCR – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The company’s […]

Related Keywords

California , United States , San Diego , America , , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Zacks Investment Research , Renaissance Technologies , America Corp , York Mellon Corp , Venture Management , Metacrine Inc , Get Rating , Sachs Group , New York Mellon Corp , Company Profile , Metacrine , Nasdaq Mtcr , Mtcr , Medical , Downgrade ,

© 2025 Vimarsana